These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 36853491

  • 1. CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma.
    Wu N, Zhu D, Li J, Li X, Zhu Z, Rao Q, Hu B, Wang H, Zhu Y.
    J Endocrinol Invest; 2023 Aug; 46(8):1573-1587. PubMed ID: 36853491
    [Abstract] [Full Text] [Related]

  • 2. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
    Jian M, Du Q, Zhu D, Mao Z, Wang X, Feng Y, Xiao Z, Wang H, Zhu Y.
    J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
    [Abstract] [Full Text] [Related]

  • 3. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
    Wang S, Wang A, Zhang Y, Zhu K, Wang X, Chen Y, Wu J.
    BMC Endocr Disord; 2021 Nov 23; 21(1):235. PubMed ID: 34814904
    [Abstract] [Full Text] [Related]

  • 4. Silencing circOMA1 Inhibits Osteosarcoma Progression by Sponging miR-1294 to Regulate c-Myc Expression.
    Shi Y, Tian Y, Sun X, Qiu Y, Zhao Y.
    Front Oncol; 2022 Nov 23; 12():889583. PubMed ID: 35493998
    [Abstract] [Full Text] [Related]

  • 5. NEK2 regulates cellular proliferation and cabergoline sensitivity in pituitary adenomas.
    Jian F, Sun Y, Sun Q, Zhang B, Bian L.
    J Cancer; 2021 Nov 23; 12(7):2083-2091. PubMed ID: 33754007
    [Abstract] [Full Text] [Related]

  • 6. circOMA1-Mediated miR-145-5p Suppresses Tumor Growth of Nonfunctioning Pituitary Adenomas by Targeting TPT1.
    Du Q, Hu B, Feng Y, Wang Z, Wang X, Zhu D, Zhu Y, Jiang X, Wang H.
    J Clin Endocrinol Metab; 2019 Jun 01; 104(6):2419-2434. PubMed ID: 30721952
    [Abstract] [Full Text] [Related]

  • 7. MicroRNA-93 mediates cabergoline-resistance by targeting ATG7 in prolactinoma.
    Wu Z, Cai L, Lu J, Wang C, Guan J, Chen X, Wu J, Zheng W, Wu Z, Li Q, Su Z.
    J Endocrinol; 2018 Sep 01. PubMed ID: 30389900
    [Abstract] [Full Text] [Related]

  • 8. miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma.
    Hu B, Mao Z, Du Q, Jiang X, Wang Z, Xiao Z, Zhu D, Wang X, Zhu Y, Wang H.
    Brain Res Bull; 2019 Jul 01; 149():21-31. PubMed ID: 30946881
    [Abstract] [Full Text] [Related]

  • 9. The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment.
    Liu YT, Liu F, Cao L, Xue L, Gu WT, Zheng YZ, Tang H, Wang Y, Yao H, Zhang Y, Xie WQ, Ren BH, Xiao ZH, Nie YJ, Hu R, Wu ZB.
    Acta Neuropathol; 2020 Sep 01; 140(3):377-396. PubMed ID: 32572597
    [Abstract] [Full Text] [Related]

  • 10. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
    Tang C, Sun R, Wen G, Zhong C, Yang J, Zhu J, Cong Z, Luo X, Ma C.
    Cell Death Dis; 2019 Apr 18; 10(5):335. PubMed ID: 31000722
    [Abstract] [Full Text] [Related]

  • 11. Role of TGF-β1/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma.
    Hu B, Mao Z, Jiang X, He D, Wang Z, Wang X, Zhu Y, Wang H.
    Brain Res; 2018 Nov 01; 1698():204-212. PubMed ID: 30055965
    [Abstract] [Full Text] [Related]

  • 12. Treatment of Prolactinoma.
    Inder WJ, Jang C.
    Medicina (Kaunas); 2022 Aug 13; 58(8):. PubMed ID: 36013562
    [Abstract] [Full Text] [Related]

  • 13. ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways.
    Zhu J, Tang C, Cong Z, Yuan F, Cai X, Yang J, Ma C.
    Endocr Relat Cancer; 2021 Dec 13; 29(2):33-46. PubMed ID: 34821219
    [Abstract] [Full Text] [Related]

  • 14. DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma.
    Yao H, Tang H, Zhang Y, Zhang QF, Liu XY, Liu YT, Gu WT, Zheng YZ, Shang HB, Wang Y, Huang JY, Wei YX, Zhang X, Zhang J, Wu ZB.
    Cancer Lett; 2019 Sep 10; 459():135-144. PubMed ID: 31176743
    [Abstract] [Full Text] [Related]

  • 15. Management of Dopamine Agonist-Resistant Prolactinoma.
    Maiter D.
    Neuroendocrinology; 2019 Sep 10; 109(1):42-50. PubMed ID: 30481756
    [Abstract] [Full Text] [Related]

  • 16. MicroRNA expression profile of bromocriptine-resistant prolactinomas.
    Wu ZB, Li WQ, Lin SJ, Wang CD, Cai L, Lu JL, Chen YX, Su ZP, Shang HB, Yang WL, Zhao WG.
    Mol Cell Endocrinol; 2014 Sep 10; 395(1-2):10-8. PubMed ID: 25064468
    [Abstract] [Full Text] [Related]

  • 17. MicroRNA-Mediated Drug Repurposing Unveiled Potential Candidate Drugs for Prolactinoma Treatment.
    Aydin B, Arslan S, Bayraklı F, Karademir B, Arga KY.
    Neuroendocrinology; 2022 Sep 10; 112(2):161-173. PubMed ID: 33706313
    [Abstract] [Full Text] [Related]

  • 18. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
    Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, Barlier A, Saveanu A.
    Eur J Endocrinol; 2008 May 10; 158(5):595-603. PubMed ID: 18426817
    [Abstract] [Full Text] [Related]

  • 19. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P, Jaskuła M, Waśko R, Wołuń M, Sowiński J.
    Pol Arch Med Wewn; 2003 May 10; 109(5):489-95. PubMed ID: 14768178
    [Abstract] [Full Text] [Related]

  • 20. Circular RNA OMA1 regulates the progression of breast cancer via modulation of the miR‑1276/SIRT4 axis.
    Xu L, Xu K, Xiang L, Yan J.
    Mol Med Rep; 2021 Oct 10; 24(4):. PubMed ID: 34414449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.